HC Wainwright reaffirmed their buy rating on shares of Leap Therapeutics (NASDAQ:LPTX - Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $5.50 price objective on the stock.
Leap Therapeutics Price Performance
Shares of Leap Therapeutics stock traded down $0.66 during trading hours on Thursday, hitting $2.59. 1,145,855 shares of the company's stock traded hands, compared to its average volume of 378,297. The stock has a market capitalization of $99.25 million, a price-to-earnings ratio of -1.34 and a beta of 0.17. Leap Therapeutics has a 12-month low of $1.68 and a 12-month high of $4.79. The company has a fifty day simple moving average of $3.01 and a 200-day simple moving average of $2.75.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Valence8 US LP purchased a new position in Leap Therapeutics in the third quarter valued at approximately $48,000. HighTower Advisors LLC bought a new stake in shares of Leap Therapeutics in the third quarter valued at $65,000. HB Wealth Management LLC raised its stake in shares of Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company's stock valued at $150,000 after buying an additional 26,150 shares during the period. Marshall Wace LLP lifted its position in shares of Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company's stock valued at $156,000 after buying an additional 58,094 shares during the last quarter. Finally, Exome Asset Management LLC bought a new position in shares of Leap Therapeutics during the 3rd quarter worth $264,000. 30.46% of the stock is currently owned by hedge funds and other institutional investors.
Leap Therapeutics Company Profile
(
Get Free Report)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Featured Stories
Before you consider Leap Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Leap Therapeutics wasn't on the list.
While Leap Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
